A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.
Amir Jazaeri, MD
Amir Jazaeri, MD, is the Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology at MD Anderson Cancer Center.
Articles by Amir Jazaeri, MD
An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.
Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving the way for targeted therapies.
Latest Updated Articles
The Prognostic Value of Residual Disease in Ovarian CancerPublished: August 22nd 2025 | Updated:
A New Hope: Fighting Ovarian Cancer at its WeakestPublished: August 20th 2025 | Updated: